Clenoliximab

Clenoliximab

Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

Uses

Investigated for use/treatment in rheumatoid arthritis.

How Clenoliximab works

Clenoliximab is a macaque-human chimeric monoclonal antibody (immunoglobulin G4)that binds specifically to the CD4 receptor present on T-lympocytes (Helper T lymphocytes). CD-4 lymphocytes are implicated in the pathogenesis of rheumatoid arthritis (RA). Clenoliximab coats the CD4 T-lymphocytes and thus down-modulates the CD4 T-lympocytes in a dose and concentration-dependent manner without decreasing the amount of CD4 T-lympocytes in circulation.

Clenoliximab

Trade Name	Clenoliximab
Generic	Clenoliximab
Clenoliximab Other Names	Clenoliximab
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	August 5, 2021 at 12:40 pm

Structure

Table Of contents

• Clenoliximab
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Innovators Monograph

You find simplified version here Clenoliximab